Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

BPRG up 10%. SEO +8%. Out of court settlement????!!!

That's the debate, but no firm news as far as I can gather. As usual, it's a little difficult to determine the wheat from the chaff!! ;-))

The prices would indicate an out of court settlement, which would be the best solution to both parties. Did you see ARX? I bought a shit load at 14p when it dropped 20%! (ONly lasted 1 minute) LOL!! Similar circumstances with WMK proceeding with the court case.

I do have WMK on my watchlist - potential short of course. Interesing you mention it as it has made a cracking reversal today at last support level. If it gets well up into yesterday's candle, it may be moved to the potential long list.

Update from over the road is we are all arguing TA. I'm amazed after yesterday that no-one has mentioned the court. It was all we discussed then. Amazing how focus can shift so quickly. Price rise for both BPRG and SEO may simply be the fact it is at last underway - sell the rumour, buy the fact, as it were.

We'll see.

Aerotus - finally got an answer. They seem to be expecting something after court closes.

Excellent. Keep me posted. Cheers

Will try, but as someone who is not like-minded, as it were, I don't easily get the answer when I ask - if you get my drift.

LOL

Just read the mysite and its been confirmed the Broker Note is out! This guy has seen it himself and its fair value is 1.30! Note is being sent to institutions on Monday morning! WHOOOPEEEEE

If that is the case well done on finding this out...

Finally, the tides have turned!!! I smell burning!! Serves them damn right! I told them not to play with fire. Monday will see a mark-up of 10% believe you me!

Have reported your findings on ADVFN. Hope you don't mind.

Short or long Big Al - what to do?

I have to say that the ADVFN poster who claims to have seem the brokers note @ 1.30 has never posted on the BPRG thread previously

aol - for me it's still a hung jury. Great for the shorters from Monday to Wednesday, but a good comeback by the bulls yesterday and today.

I don't work on news or broker's notes really. I just follow my charts when they say there's a trade on and I keep an eye on L2. At present it's more likely to be a short than a long, but that could change in another trading day. That's the beauty of the market.

Aerotus , what message do you get when you try accessing advfn at work ?

Me and belabed had a similar problem a while back and it was because the security software had decided to reclassify advfn as a gambling site. Spoke to advfn and they sorted it with the software firm , may be able to do something similar for you.

Big Al , the bprg thread across the road is for serious investment discussion ... not a bloody dating site for you and belabed :-)

LOL!!

RNS - Not particularly exciting as far as I can work out.

BioProgress PLC
12 July 2004

Press Release 12 July 2004


BioProgress plc

('BioProgress' or 'the Company')

Pre-close statement

BioProgress plc, a provider of innovative delivery mechanisms for the
pharmaceutical oral dosage markets, issues the following pre-close statement in
advance of its Interim Results for the six months ended 30 June 2004, which are
scheduled for announcement in September 2004.

Since the beginning of 2004, significant licensing deals have been signed with
FMC BioPolymer for the NROBE(R) dosage form, and with Perrigo Company for the
TABWRAP(R) dosage form. BioProgress has also acquired edible film assets from
Aquafilm LLC which has since been renamed BioTec Films LLC. In this regard, the
Company has successfully completed production trials of films for NROBE(R) in
Tampa and will demonstrate film production to Wyeth later this month as part of
the due diligence process on the SWALLOW technology being conducted by Wyeth,
following the signing of the licensing option agreement.

BioProgress advises that all of the agreements referred to above are progressing
well. The acquisition of the Tampa facility from Aquafilm LLC has been
important in accelerating the Company's ability to meet the film production
requirements of its XGEL(R) technology licensees. The 'in-the-mouth' dissolving
film market continues to grow, with few suppliers and considerable demand for
products. BioProgress is expanding its current US product offering into Europe
and is in discussions to develop both over-the-counter medicines opportunities
for this technology and also veterinary medicines applications.

BioProgress has also announced its intention to seek a listing on the NASDAQ
National Market. Discussions continue with potential US advisors, and a further
announcement will be made when appropriate.

The patent entitlement proceedings against Stanelco Fibre Optics Limited are now
the subject of court hearings which started on July 8th, and BioProgress remains
confident that it has a very strong case.

Graham Hind, Chief Executive Officer of BioProgress plc, said: 'I am very
pleased with the progress that has been made so far in licensing out our
technologies. We are partnering with some major international names and,
excluding BioTec Film's expected contribution this year, we anticipate
significant revenues from royalties, machines and film sales to start flowing to
BioProgress from 2005 onwards. Our balance sheet is strong, with cash resources
of more than 12 million, and I continue to be extremely confident about the
prospects for our business going forward. I look forward to giving a detailed
update when we announce our Interim Results in September.'


Forward-Looking Information.
The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934. This announcement contains certain 'forward-looking
statements' within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and are
subject to uncertainty and changes in circumstances. Actual results may vary
materially from the expectations contained in the forward-looking statements.
The forward-looking statements in this release include statements addressing
future financial and operating results and the timing and benefits of the
reorganisation. Detailed information about factors pertinent to the business of
the company that could cause actual results to differ is set forth in the
Company's filings with the Securities and Exchange Commission. The Company is
under no obligation to (and expressly disclaim any such obligation to) update or
alter its forward-looking statements whether as a result of new information,
future events or otherwise.



- Ends -


For further information:
BioProgress plc

Graham Hind, Chief Executive Tel: +44 (0) 1354 655 674
grahamhind@bioprogress.com www.bioprogress.com


Media enquiries:
Bankside
Henry Harrison-Topham / Heather Salmond Tel: +44 (0) 20 7444 4140
henry.ht@bankside.com www.bankside.com

Notes to editors:
BioProgress listed on AIM in May 2003 and is engaged in the research,
development, and design of patented encapsulation systems that use water soluble
and biodegradable films for the dietary supplement, pharmaceutical and other
sectors. The Company's patent portfolio comprises over sixty patents within
sixteen patent families and has product development agreements and strategic
alliances with several global companies. BioProgress aims to provide a cost
effective and animal-free encapsulation process for pharmaceutical drugs in
liquids, tablets and powders, thereby addressing the needs of the entire market
for oral dosage forms while providing novel delivery mechanisms not possible
with traditional processes.

The Company has also developed patented and licensed the world's first flushable
ostomy pouch that offers a newly enhanced quality of life not previously
possible for the end user. Market research shows the global ostomy market to be
worth $1 billion annually.

The Company's business model provides it with several significant revenue
streams including sales of encapsulating machines and film, plus licence and
fees for research development services.


This information is provided by RNS
The company news service from the London Stock Exchange

Big Al, whats the latest gossip going on? Very quiet in here today!

Not much really - I've not taken much of an interest today to be honest.

Wolstenhulme reckons the BN will make little difference to the share price (correct IMO) and the rest are just taking up valuable oxygen as usual. DK has "bottomed out" numerous times and Robby George's sole contribution has been an unending stream of "LOL!"s

Katie was in court - oh no she wasn't came a multitude of replies and The Chartist has been filtered by more people than actually post by the look of it. ;-))

It's all a fairly sorry reminder of why I gave up many of the free BB's years ago. Rational discussion is not an option, which is a shame when there's cash at stake.

Nice RNS for the believers, but they popped it up and dropped it back very quickly this morning. Price is at the critical level I was mentioning last week IMO. Where to is the question. No MM moves since 09:35 seems to be making a few nervous.

Al

Thanks for the update Big Al, I too am a bit surprised that the price has not risen strongly today. I think shorters still believe they have a chance, WRONG! GH will be bringing out further rapid bang RNS news which will see the shorters off. Expecting another 2 RNS's this week at least.